Clinical trials
Phase 2 Multiple Myeloma trials in Israel
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
18 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2015 | 2 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 7 |
| Active, not recruiting | 4 |
| Recruiting | 3 |
| Withdrawn | 2 |
| Terminated | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Janssen Research & Development, LLC | 7 |
| Tel-Aviv Sourasky Medical Center | 2 |
| Arbeitsgemeinschaft medikamentoese Tumortherapie | 1 |
| Beth Israel Deaconess Medical Center | 1 |
| Cellectar Biosciences, Inc. | 1 |
| Hadassah Medical Organization | 1 |
| Karyopharm Therapeutics Inc | 1 |
| Merck Sharp & Dohme LLC | 1 |
| Novartis Pharmaceuticals | 1 |
| Polina Stepensky | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Myeloma | 18 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 |
| Lymphoma, Non-Hodgkin | 2 |
| Neoplasms | 2 |
| Neoplasms, Plasma Cell | 2 |
| Recurrence | 2 |
| Smoldering Multiple Myeloma | 2 |
| Blood Protein Disorders | 1 |
| Hematologic Diseases | 1 |
| Hematologic Neoplasms | 1 |
Trials
Showing 1 to 18 of 18. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.